The FIDELIO Study Podcast Robert TotoGeorge Bakris Commentary Open access 24 March 2022 Pages: 823 - 828
Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus Stefan PleusGuido FreckmannRolf Hinzmann Commentary Open access 13 April 2022 Pages: 829 - 846
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review John P. H. WildingMarc EvansStefano Del Prato Review Open access 20 March 2022 Pages: 847 - 872
Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications Virginia BellidoJulia MartínezAlbert Lecube Review Open access 25 March 2022 Pages: 873 - 888
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently Marc EvansAngharad R. MorganW. David Strain Review Open access 29 March 2022 Pages: 889 - 911
Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies Stewart B. HarrisErika B. ParenteJanaka Karalliedde Review Open access 30 March 2022 Pages: 913 - 930
The Emerging Role of Continuous Glucose Monitoring in the Management of Diabetic Peripheral Neuropathy: A Narrative Review Evanthia GouveriNikolaos Papanas Review Open access 08 April 2022 Pages: 931 - 952
Level of Agreement and Correlation Between the Estimated Hemoglobin A1c Results Derived by Continuous or Conventional Glucose Monitoring Systems Compared with the Point-of-Care or Laboratory-Based Measurements: An Observational Study Ayman A. Al HayekSamia H. SobkiMohamed A. Al Dawish Original Research Open access 20 March 2022 Pages: 953 - 967
The Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in China: Results from the Cross-Sectional CAPTURE Study Tianpei HongZongxun YanDi Zhao Original Research Open access 21 March 2022 Pages: 969 - 981
Impact of My Dose Coach App Frequency of Use on Clinical Outcomes in Type 2 Diabetes Ambika Gopalakrishnan UnnikrishnanVijay ViswanathanLeonardo Mancillas-Adame Original Research Open access 22 March 2022 Pages: 983 - 993
A Therapeutic Vibrating Insole Device for Postural Instability in Older People with Type 2 Diabetes: A Randomized Control Study Isabelle Bourdel-MarchassonSophie C. ReguemeAlan J. Sinclair Original Research Open access 23 March 2022 Pages: 995 - 1006
The Risk Factors Potentially Influencing Hospital Admission in People with Diabetes, Following SARS-CoV-2 Infection: A Population-Level Analysis Adrian H. HealdDavid A. JenkinsWilliam Ollier Original Research Open access 24 March 2022 Pages: 1007 - 1021
Effects of Pentoxifylline on Serum Markers of Diabetic Nephropathy in Type 2 Diabetes Fatemeh MoosaieSoghra RabizadehAlireza Esteghamati Original Research Open access 05 April 2022 Pages: 1023 - 1036
Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors Adrian H. HealdDavid A. JenkinsJ. Martin Gibson Original Research Open access 13 April 2022 Pages: 1037 - 1051
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M) S. R. AravindKiran P. SinghBhaswati Mukherjee Original Research Open access 14 April 2022 Pages: 1053 - 1071
Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study Shinya FurukawaTeruki MiyakeYoichi Hiasa Original Research Open access 15 April 2022 Pages: 1073 - 1082
Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study Teruki MiyakeOsamu YoshidaYoichi Hiasa Study Protocol Open access 21 March 2022 Pages: 1083 - 1096
Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting Manoj ChadhaAshok Kumar DasViswanathan Mohan Practical Approach Open access 25 March 2022 Pages: 1097 - 1114
Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a Type 1 Diabetic Patient David S. H. BellTerri Jerkins Case Report Open access 07 April 2022 Pages: 1115 - 1119
Cost-Effectiveness of Intermittently Scanned Continuous Glucose Monitoring Versus Advanced Hybrid Closed-Loop Systems in Type 1 Diabetes: Comment on Jendle et al. Fleur Levrat-GuillenTara Ghazi Letter Open access 11 April 2022 Pages: 1121 - 1123
A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden J. JendleM. I. BuompensiereO. Cohen Letter Open access 11 April 2022 Pages: 1125 - 1129
Correction to: Cost-Effectiveness Evaluation of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Study Michael MouniéNadège CostaI. Moura Correction Open access 22 March 2022 Pages: 1131 - 1132